Form 4: Ventyx Biosciences Chief Medical Officer Acquires 85,000 Stock Options

Ventyx Biosciences' Chief Medical Officer, Mark S. Forman, was granted 85,000 stock options on January 2, 2025, according to a recent SEC filing.

Summary

• Mark S. Forman, the Chief Medical Officer of Ventyx Biosciences, Inc., was granted 85,000 stock options on January 2, 2025.
• The options have an exercise price of $2.14 per share.
• The options vest monthly over a four-year period, with 1/48th of the total shares vesting each month, starting from the vesting commencement date of January 2, 2025.
• The options expire on January 2, 2035.
• The filing indicates that these options were granted directly to Mr. Forman.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no indications of negative news or concerns.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the options is dependent on the future performance of Ventyx Biosciences' stock price.
• If the stock price does not increase above the exercise price, the options may not be valuable to the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting schedule of 1/48th per month over four years is a typical vesting structure for executive stock options.
• The exercise price of $2.14 is specific to Ventyx Biosciences and its current stock valuation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to increase the company's value.
• The Chief Medical Officer is incentivized to perform well to realize the value of the options.

Key Dates

Keywords

stock options, Ventyx Biosciences, executive compensation, Form 4, insider trading, Mark S. Forman, Chief Medical Officer